Evidence map›Paper›PMID 40442579›Full record

ArticleClinical proteomics2025

Integrating multimodal data to predict the progression of hormone-sensitive prostate cancer.

Xiangfu Lu, Chenxi Pan, Luhan Yao, Jiayu Wan, Xiaolong Xu, Wei Wang, Xiangying Wang, Xiaoyun Liu, Zhonghua Jin, Hongyu Wang and 2 more

Abstract read
In one paragraph

Article in Clinical proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiangfu Lu *Department of Urology, 967 th hospital of PLA Joint Logistics Support Force, No.80 Shengli Road, Dalian, 116014, PR China.
Chenxi Pan *State key laboratory of fine chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, School of Bioengineering, Dalian University of Technology, Dalian, 116023, PR China.
Luhan Yao *School of Information and Communication Engineering, Dalian University of Technology, Dalian, Dalian, 116023, PR China.
Jiayu Wan *School of Information and Communication Engineering, Dalian University of Technology, Dalian, Dalian, 116023, PR China.
Xiaolong XuDepartment of Urology, The Second Hospital of Dalian Medical University, No.467 Zhongshan Road, Dalian, 116023, PR China.
Wei WangDepartment of Urology, The Second Hospital of Dalian Medical University, No.467 Zhongshan Road, Dalian, 116023, PR China.
Xiangying WangState key laboratory of fine chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, School of Bioengineering, Dalian University of Technology, Dalian, 116023, PR China.
Xiaoyun LiuDepartment of Urology, The Second Hospital of Dalian Medical University, No.467 Zhongshan Road, Dalian, 116023, PR China.
Zhonghua JinDepartment of chest surgery, The Second Hospital of Dalian Medical University, No.467 Zhongshan Road, Dalian, 116023, PR China.
Hongyu WangSchool of Information and Communication Engineering, Dalian University of Technology, Dalian, Dalian, 116023, PR China. whyu@dlut.edu.cn.
Yi HeDepartment of Urology, The Second Hospital of Dalian Medical University, No.467 Zhongshan Road, Dalian, 116023, PR China. heyi_gzr@163.com.
Bo YangDepartment of Urology, The Second Hospital of Dalian Medical University, No.467 Zhongshan Road, Dalian, 116023, PR China. yangbo20160101@163.com.

Funding

"1+X" program for Clinical Competency enhancement-Clinical Research Incubation Project and the Second Hospital of Dalian Medical University 2022LCYJYB08"1+X" program for Clinical Competency enhancement-Clinical Research Incubation Project and the Second Hospital of Dalian Medical University 2022LCYJZD02"1+X"Research Project of the Second Hospital of Dalian Medical University CYQH2024016Basic Research Operating Expenses for Higher Education Institutions DUT22YG110Dalian Science and Technology Innovation Fund Project 2022JJ11CG002
6 · The paper itself

Abstract

Identifying the population at risk of rapid progression from hormone-sensitive prostate cancer (HSPC) to lethal castration-resistant prostate cancer (CRPC) is a challenge. This work has highlighted important prognostic insights based on proteomics data, magnetic resonance imaging (MRI) and histopathological specimens. We retrospectively developed a multi-omics-based model based on 77 patients with HSPC. In order to identify the features related to survival time under each mode, we used the Boruta algorithm for feature screening. In order to demonstrate the effectiveness of our selected features, we used six machine learning methods to validate the classification of the selected features for each mode. A total of 63 proteome signatures, 60 HE signatures, 56 T2WI signatures, and 54 ADC signatures were identified as features related to the speed of HSPC progression. Ultimately, 30 multi-omics-based features were determined by the least absolute shrinkage and selection operator (LASSO) method and multivariate cox regression. In order to stratify patients with significant disparities in progress, a nomogram model was developed, of which the C-index was 0.906. Accordingly, the developed model could help identify patients who are at a high risk of rapid CRPC progression, and aid clinicians in guiding personalized clinical management and decision-making.

Indexed as

Hormone-sensitive prostate cancer, Histopathology, Proteome, Magnetic resonance imaging, Machine learning

Identifiers

PMID40442579
PMCPMC12121097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.